Trastuzumab improves survival for HER2-positive breast cancer
the ONA take:
According to a recent study published in the Journal of Clinical Oncology, researchers performed a joint analysis of two trials comparing chemotherapy with and without trastuzumab and found that trastuzumab improved overall survival in patients with early-stage human epidermal growth factor receptor 2 (HER2)-positive breast cancer.
Across the two studies, over 4,000 patients with node-positive HER2-positive breast cancer were randomly assigned to receive doxorubicin and cyclophosphamide, followed by paclitaxel with or without trastuzumab.
Results showed that the 10-year overall survival was 84% for those who received trastuzumab compared with 75% for those who did not. In addition, the 10-year disease-free survival was 74% for those that received trastuzumab versus 62% for who that did not receive the anti-HER2 monoclonal antibody.
In addition, the incidence of cardiotoxicity was observed in 3% of patients that received trastuzumab and most patients who experienced cardiac adverse effects recovered.
The early results of the same studies in this joint analysis lead to the approval of trastuzumab for the adjuvant treatment of HER2-positive breast cancers by the U.S. Food and Drug Administration in 2006. Now, after 10 years, the results show that the addition of trastuzumab improves overall survival and disease-free survival.
Trastuzumab improved overall survival in early-stage HER2-positive breast cancer.
- Immunotherapy May Benefit Some Patients with Papillary Thyroid Carcinoma
- New Study Questions Standard Dosage for Treating Metastatic Non-Small Cell Lung Cancer
- Clinical Trials May Benefit Oncology Patients
- Breast Cancer Overdiagnosis Also a Result of Screening Mammography Programs
- Prostate-specific PET and CT Imaging Improves Detection of Disease and Patient Care
- Survivorship Care Plans: Providing A Blueprint for Health Care After Cancer
- Multifaceted Role of the Nurse Navigator Includes Palliative, Supportive Care
- Cancer Recurrence Fear Reduced by Novel Psychological Intervention
- Patient Navigators Found to Boost Lung Cancer Screening Rates
- Breast Cancer Diagnosis and Nurse Navigation Survey
- Novel 3D Marker Reduces Radiation, Improves Cosmesis in Breast Conserving Surgery
- Rates at Some Milestones May Indicate Clinical Trial Results for Immunotherapeutics
- Cancer Risks for BRCA1/2 Mutation Carriers Determined by Age, Family History, Mutation Location
- Long-Term Use of TPO Receptor Agonist Safe in CLL-Associated Immune Thrombocytopenia
- Savolitinib Active, Tolerable in Subset of Advanced Papillary Renal Cell Cancer
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|